A variety of drugs inhibit the conversion of arachidonic acid to prostaglandin G 2 by the cyclooxygenase (COX) activity of prostaglandin endoperoxide synthases. Several modes of inhibitor binding in the COX active site have been described including ion pairing of carboxylic acid containing inhibitors with Arg-120 of COX-1 and COX-2 and insertion of arylsulfonamides and sulfones into the COX-2 side pocket. Recent crystallographic evidence suggests that Tyr-385 and Ser-530 chelate polar or negatively charged groups in arachidonic acid and aspirin. We tested the generality of this binding mode by analyzing the action of a series of COX inhibitors against site-directed mutants of COX-2 bearing changes in Arg-120, Tyr-355, Tyr-348, and Ser-530. Interestingly, diclofenac inhibition was unaffected by the mutation of Arg-120 to alanine but was dramatically attenuated by the S530A mutation. Determination of the crystal structure of a complex of diclofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an inverted conformation with its carboxylate group hydrogen-bonded to Tyr-385 and Ser-530. This finding represents the first experimental demonstration that the carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to a COX enzyme in an orientation that precludes the formation of a salt bridge with Arg-120. Mutagenesis experiments suggest Ser-530 is also important in time-dependent inhibition by nimesulide and piroxicam.
A variety of drugs inhibit the conversion of arachidonic acid to prostaglandin G 2 by the cyclooxygenase (COX) activity of prostaglandin endoperoxide synthases. Several modes of inhibitor binding in the COX active site have been described including ion pairing of carboxylic acid containing inhibitors with Arg-120 of COX-1 and COX-2 and insertion of arylsulfonamides and sulfones into the COX-2 side pocket. Recent crystallographic evidence suggests that Tyr-385 and Ser-530 chelate polar or negatively charged groups in arachidonic acid and aspirin. We tested the generality of this binding mode by analyzing the action of a series of COX inhibitors against site-directed mutants of COX-2 bearing changes in Arg-120, Tyr-355, Tyr-348, and Ser-530. Interestingly, diclofenac inhibition was unaffected by the mutation of Arg-120 to alanine but was dramatically attenuated by the S530A mutation. Determination of the crystal structure of a complex of diclofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an inverted conformation with its carboxylate group hydrogen-bonded to Tyr-385 and Ser-530. This finding represents the first experimental demonstration that the carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to a COX enzyme in an orientation that precludes the formation of a salt bridge with Arg-120. Mutagenesis experiments suggest Ser-530 is also important in time-dependent inhibition by nimesulide and piroxicam.
The cyclooxygenase (COX) 1 activity of prostaglandin endoperoxide synthase catalyzes the incorporation of two molecules of O 2 into arachidonic acid to yield the hydroperoxy endoperoxide, prostaglandin G 2 (PGG 2 ) (1, 2). PGG 2 diffuses from the cyclooxygenase active site and binds at the peroxidase active site where it is reduced to the hydroxy endoperoxide, PGH 2 , the precursor to prostaglandins, thromboxane, and prostacyclin (3) . Two COX isoforms exist that differ in expression pattern, mode of regulation, and biological function (4) . COX-1 is generally considered the homeostatic form of the enzyme as it is constitutively expressed in a number of tissues, whereas COX-2 is sensitive to induction in many tissues by a broad range of physiological and pathological stimuli (5) . Inhibition of COX enzymes by non-steroidal anti-inflammatory drugs (NSAIDs) accounts for their anti-inflammatory and analgesic activities, as well as their gastrointestinal toxicity (6) . Development of selective COX-2 inhibitors has reduced the gastrointestinal liability (7) .
Structural and functional analysis is providing an increasingly detailed picture of the molecular determinants of COXsubstrate and COX-inhibitor interactions (3). COX-1 and COX-2 have very similar structures characterized by a membrane-binding domain comprised of amphipathic helices forming the entrance to a long hydrophobic channel (8 -10) . This channel leads deep inside the protein, and at its upper end comprises the cyclooxygenase active site. The cyclooxygenase active site is separated from the opening near the membranebinding domain by a constriction made up of the residues Arg-120, 2 Tyr-355, and Glu-524 (see Fig. 1 ). Arachidonic acid, when bound productively for turnover, is positioned with its carboxylic acid ion-paired to Arg-120, its 13-pro-S-hydrogen adjacent to the catalytically important Tyr-385, and its -end projecting into a channel that abuts Gly-533 (11, 12) . Crystal structures of COX enzymes with carboxylic acid-containing NSAIDs show that the inhibitors are positioned in a similar fashion with their carboxylates coordinated to Arg-120 and their aromatic functionality projecting into the cyclooxygenase active site toward Tyr-385 (8, 9 COX-2 bind in the cyclooxygenase active site above Arg-120 and insert their sulfonamide or sulfone groups into a side pocket bordered by Val-523 (9) .
Recently, x-ray analysis of a cocrystal of arachidonic acid with apoCOX-2 uncovered a unique conformation of bound substrate in which the arachidonic acid molecule was inverted with its carboxylate coordinated to Ser-530 and Tyr-385 (13) (see Fig. 1 ). In this conformation, the alkyl chain of arachidonate projected down toward Arg-120 and then bent sharply up so that its -end was positioned adjacent to Leu-531 and Met-535. This orientation was proposed to reflect a non-productive or inhibitory conformation of bound substrate although there is no evidence for substrate inhibition in our hands at concentrations of arachidonic acid up to 100 M. Despite the uncertainty about the physiological relevance of this conformation of arachidonic acid, its unique orientation identified Tyr-385 and Ser-530 as residues that can cooperate in the chelation of negative charges or electron-rich centers. Indeed, we found that such an interaction is a critical determinant of the selectivity of aspirin for covalent modification of Ser-530 as mutagenesis of Tyr-385 to Phe reduces aspirin acetylation of Ser-530 by over 90% (14) . Hydrogen bonding by Tyr-385 is proposed to stabilize the negative charge of the tetrahedral intermediate that develops during Ser-530 acetylation (14) .
The structural and functional evidence for the importance of Tyr-385 and Ser-530 in the chelation of ligands prompted us to ask whether these groups might be important for the interaction of cyclooxygenases with other inhibitors. Because Ser-530 is not essential for cyclooxygenase activity, the S530A mutant represents an enzyme that is catalytically active but unable to participate with Tyr-385 in chelation (15) . Thus, we prepared this mutant and probed its sensitivity to inhibition by representatives of all the major structural classes of NSAIDs. The results suggest that Tyr-385/Ser-530 chelation is critical for inhibition of COX-2 by the clinically used NSAIDs, diclofenac, piroxicam, and nimesulide. To test this hypothesis, we undertook structural studies of COX-2-diclofenac complexes that revealed that diclofenac is bound in an orientation in which its carboxylic acid is coordinated to Tyr-385 and Ser-530, analogous to the inverted orientation reported recently (13) for arachidonic acid bound to COX-2. These studies highlight the importance of Tyr-385 and Ser-530 to ligand association with COX-2 and identify a new binding mode that appears to be important for COX inhibition by some classes of NSAIDs.
EXPERIMENTAL PROCEDURES
Materials-Arachidonic acid (5Z,8Z,11Z,14Z-eicosatetraenoic acid) and [ 14 C]arachidonic acid were purchased from Nu-Chek-Prep (Elysian, MN) and PerkinElmer Life Sciences, respectively. Electrophoresis and chromatography reagents were purchased from Bio-Rad. Ketorolac was purchased from Cayman Chemical (Ann Arbor, MI). All other inhibitors and reagents were purchased from Sigma-Aldrich unless otherwise stated.
Mutant Construction-Site-directed mutagenesis was performed on a mouse COX-2 (mCOX-2) pBSϩ vector (Stratagene, La Jolla, CA) using the QuikChange mutagenesis kit (Stratagene). The R120A mutant was subcloned into the mCOX-2 pVL1393 baculovirus expression vector (Pharmingen) using the BlpI and EcoRI restriction sites, the Y355F mutant was subcloned using the EcoNI and EcoRI restriction sites, and the S530A was subcloned by use of the StuI restriction site in mCOX-2 and the XmaI restriction site present in both the pBSϩ and pVL1393 vectors. The subcloned regions were fully sequenced to ensure no accidental mutations were incorporated.
Protein Expression and Purification-Wild-type and mutant proteins were expressed in SF-9 cells and purified as described (11) .
Peroxidase Assays-The peroxidase activity of all purified proteins was measured using the guaiacol peroxidase assay as described (16) .
Cyclooxygenase Activity-Oxygen consumption was measured with a Gilson Model 5/6 oxygraph (Gilson Medical Electronics, Inc., Middletown, WI) fitted with a Clark electrode and a thermostatted cuvette set to 37°C in a 100 mM Tris-HCl, 500 M phenol, pH 8.0, buffer (1.3 ml). The rate and magnitude of oxygen uptake were determined in the manner described previously (17) using 150 nM purified protein reconstituted with 2 equivalents of hematin and 100 M arachidonic acid.
Cyclooxygenase Inhibition Assays-COX assays were performed with purified protein reconstituted with two equivalents of hematin in 100 mM Tris-HCl, 500 M phenol, pH 8.0, buffer for the indicated time with [ 14 C]arachidonic acid at 37°C. All assays were terminated and analyzed by thin layer chromatography in the manner described previously (18) . Time-dependent inhibition assays were performed by preincubating the inhibitor and enzyme for 20 min at 25°C and then at 37°C for 4 min prior to the addition of [
14 C]arachidonic acid (100 M final concentration) for 30 s at 37°C. High substrate concentration (100 M) was employed to ensure that assays were performed in a concentration range well above the K m of the mutant enzymes. For competitive inhibition assays, 10 l of inhibitor and 10 l of 200 M [ 14 C]arachidonic acid were added to the reaction vessel followed by 180 l of enzyme at the indicated concentration. After a 15-s incubation at 37°C, the assays were terminated, and products were determined in the manner indicated above.
Crystallography-Recombinant murine COX-2 was overexpressed in Sf21 cells in a baculovirus expression system as described previously (19) except that the initial heparin column was not used. The first anion exchange column pool was trypsinized at a ratio of 30:1 (w/w, COX-2: trypsin) for 30 min at room temperature to remove a 3-kDa C-terminal COX-2 fragment and contaminating baculovirus coat proteins 3 (20) . The proteolyzed material was run through a size exclusion column containing 5 mM glutathione in the buffer to remove any residual heme present (added back in the crystallization experiments). The rest of the purification protocols were as described (19) .
Co-crystallization was performed as described previously (9), using a concentration of 1 mM diclofenac. Amber-colored plate-like crystals appeared and grew to ϳ0.25 ϫ 0.15 ϫ 0.15 mm within 2 weeks. The crystal was flash frozen, and data were collected at the 17-ID beamline at the Advanced Photon Source on an ADSC Quantum 210 CCD detector. The crystal diffracted X-rays to 2.9-Å resolution, and the data were reduced with the HKL Suite (21) . The crystal belongs to space group P2 1 2 1 2 and with the following cell parameters: a ϭ 181.1 Å, b ϭ 135.1 Å, c ϭ 124.2 Å, ␣ ϭ ␤ ϭ ␥ ϭ 90°. Overall, 362,090 reflections were measured (67,852 unique), and an R sym of 16.1%. The structure was solved by difference Fourier methods using the COX-2/arachidonic acid complex (Protein Data Bank code 1CVU) as the initial model (13) . Two COX-2 dimers are in each asymmetric unit. The coordinates were refined using the program X-PLOR by conjugate gradient and individual temperature factor refinement protocols with bulk solvent correction (22, 23) . The current R-factors for the model are R free ϭ 30.2% and r ϭ 24.9% for all reflections in the resolution range of 20 to 2.9 Å with excellent stereochemistry (root mean square deviation of 0.008 Å and 1.5°from ideal bond lengths and angles, respectively). The current model includes protein residues 33-583, one heme molecule, five Nacetyl glucosamine sugars, one ␤-octyl-glucopyranoside, and one diclofenac molecule per monomer. The coordinates have been deposited into the Protein Data Bank under accession code 1PXX.
RESULTS
Inhibition of Mutant COX-2s-A series of site-directed mutations in murine COX-2 were constructed and expressed in insect cells from baculovirus vectors. These included S530A, R120A, Y355F, Y385F, and Y348F. Arg-120 and Tyr-355 are residues at the constriction between the lobby and the active site, and Tyr-385 and Tyr-348 are located within the active site, hydrogen-bonded to each other (Fig. 1) . All expressed mutants were purified by ion-exchange chromatography and gel filtration. The purity of the Y348F mutant was shown by densitometric scanning of 7.5% SDS-polyacrylamide gels to be 70%, whereas all other mutants were equal to or greater than 90% pure (Table I) . Table I also lists the peroxidase and cyclooxygenase activities of the purified proteins. The peroxidase activities of the mutant enzymes were all similar to the activity observed with wild-type mCOX-2, indicating that the introduced mutations did not result in gross structural perturbations of the enzyme. Some of the mutant enzymes exhibited a modest reduction in COX activity, as well as a proportional decrease in the total conversion of arachidonic acid to COX products. The cyclooxygenase activity for Y385F could not be measured as this residue is strictly required for that reaction.
The mutant proteins were tested for sensitivity to inhibition by a series of compounds that are time-dependent COX inhibitors (see Fig. 2 and Table II ). The choice of compound was made to represent the major classes of cyclooxygenase inhibitors (i.e. arylacetic acids, arylpropionic acids, enolcarboxamides, and anthranilic acids). Each inhibitor was incubated with protein for 24 min prior to the addition of arachidonic acid. The arylcarboxylic acids, indomethacin and meclofenamic acid, were equipotent against wild-type enzyme and S530A but exhibited greatly reduced inhibition of the Y355F enzyme. Indomethacin inhibition was very sensitive to mutation of Arg-120 whereas meclofenamic acid inhibition was reduced ϳ4-fold. This is consistent with the results of previous mutagenesis studies and with the crystal structure of a COX-2-indomethacin complex in which the carboxylic acid interacts with Arg-120 and Tyr-355 (bond distances of 2.4 and 3.0 Å, respectively) (9, 24 -26) .
A completely different pattern of sensitivity was exhibited by diclofenac, which is a close structural analog of meclofenamic acid. The IC 50 values for time-dependent inhibition of wildtype, R120A, and Y355F enzymes were comparable, whereas the S530A enzyme appeared completely resistant to inhibition by diclofenac. Y348F, which has been shown to affect acetylation of Ser-530 by aspirin, had no impact on inhibition by diclofenac (Fig. 3) . The arylcarboxylic acid, ketorolac, was comparable with indomethacin in that it did not inhibit R120A or Y355F, but its inhibitory potency against S530A was somewhat reduced (23-fold). Interestingly, piroxicam, which does not contain a carboxylic acid, did not exhibit time-dependent inhibition of any the three mutant proteins. Nimesulide was similar to diclofenac in that it was less potent against S530A than wild-type enzyme, but the magnitude of the difference was not as great as with diclofenac (Fig. 4) .
Because Ser-530 appeared to be an important determinant for binding three of the five time-dependent NSAIDs tested in Table I , we also determined the potency of the competitive inhibitors ibuprofen, naproxen, and mefenamic acid against the S530A mutant. The mutation caused a modest 2-fold increase in the IC 50 of ibuprofen and naproxen and a 3.7-fold increase in IC 50 of mefenamic acid (Table III) . The R120A and Y355F mutants were not included in this study, because these two side chains are important in binding the carboxylate of arachidonate, making them more sensitive to inhibition by competitive inhibitors (data not shown).
Attempts were made to investigate the nature of the alteration in inhibitory potencies of diclofenac induced by the mutation of Ser-530 to Ala. Assays were performed to evaluate its ability to act as a competitive or time-dependent inhibitor of wild-type COX-2 and S530A. Diclofenac is a potent time-dependent inhibitor of wild-type enzyme and displays no competitive inhibitory activity, even at concentrations of arachidonic acid (2 M) near its K m . No competitive inhibition of S530A was detected, and the inhibitory potency of diclofenac for S530A was reduced below the limits of detection of the time-dependent inhibition assay. Fig. 4A displays a series of plots of the rates of arachidonate oxygenation by COX-2 as a function of substrate concentrations at different concentrations of another time-dependent inhibitor, the arylsulfonamide, nimesulide. These experiments were performed by addition of enzyme to a solution containing arachidonate with nimesulide to minimize time-dependent inhibition. However, the plots are not typical of pure competitive inhibition, because increasing concentrations of nimesulide decrease the maximal rate of oxygenation so that V max is not 
TABLE I Characterization of mutant cyclooxygenases
The purities of wild-type (wt) and mutant COX-2 proteins were determined from Coomassie-stained 7.5% SDS-polyacrylamide gels. Peroxidase activities were determined using the guaiacol peroxidase assay. The cyclooxygenase activity initial rates and total product production were determined in the manner described under "Experimental Procedures." The cyclooxygenase activity of wild-type enzyme was 9.6 mol arachidonic acid oxidized/min/mg protein. Crystallography-The dramatic impact of mutation of Ser-530 on inhibition by diclofenac suggests that it binds to COX-2 in such a way as to maximize interaction with the Ser-530 hydroxyl group. To test this hypothesis, crystals of mCOX-2 were grown in the presence of diclofenac. Initial difference electron density maps clearly revealed the presence of diclofenac in the cyclooxygenase active site (Fig. 5a) . Diclofenac is bound deep in the active site, which is located at the end of a
TABLE II Time-dependent inhibition of wild-type COX-2 and COX-2 mutants by NSAIDs
Assays were performed, and the total products were determined as described under "Experimental Procedures." IC 50 values are the average of three or more determinations Ϯ S.E. Values in parentheses are the -fold differences relative to wild-type enzyme.
FIG. 2.
NSAIDs screened for inhibitory activity against the panel of mutants.
FIG. 3.
Time-dependent inhibition of cyclooxygenase activity of wild-type mCOX-2 and mCOX-2 mutants by diclofenac. Hemereconstituted purified proteins, 146 nM for wild-type mCOX-2 (E), 219 nM for R120A mCOX-2 (ࡗ), 255 nM for Y355F mCOX-2 (f), 200 nM for Y348F mCOX-2 (Ⅺ), and 130 nM for S530A mCOX-2 (OE) in 100 mM Tris-HCl, 500 M phenol, pH 8.0, were incubated with diclofenac for 20 min at 25°C, followed by a further 4-min incubation at 37°C prior to addition of 100 M [ 14 C]arachidonic acid for 30 s. Assays were terminated, and total product was assessed as described under "Experimental Procedures." channel that emanates from the helical, membrane-binding domain of cyclooxygenases (8, 9) . The inhibitor is completely enclosed within the main channel of the cyclooxygenase active site of COX-2 with no interactions in the side pocket (9) .
The carboxylate of diclofenac forms two strong hydrogen bonds to the side chains of Tyr-385 (2.7 Å) and Ser-530 (2.7 Å) at the apex of the cyclooxygenase active site (Fig. 5b) . In addition, the inhibitor forms extensive van der Waals interactions with several hydrophobic protein residues within the active site. Side chains of Tyr-385, Trp-387, Leu-384, and Leu-352 surround the phenyl group that is attached to the acetic acid moiety. The aromatic ring of the inhibitor makes contact with the main chain atoms of Met-522 and Gly-526. The bridging amino group is not engaged in any close interactions with protein atoms. The dichlorophenyl group forms van der Waals interactions with Val-349, Ala-527, Leu-531, and Val-523. Importantly, neither Tyr-355 nor Arg-120 contact the inhibitor.
The closest distance between the inhibitor and Arg-120 side chain is ϳ4.1 Å. This is consistent with the results of the mutagenesis experiments in that neither the R120A nor the Y355F mutants had a significant effect on inhibition by diclofenac.
DISCUSSION
The present results reveal that Ser-530 and Tyr-385 are important for the inhibition of COX-2 by several compounds besides aspirin. Site-directed mutagenesis of Ser-530 to Ala virtually abolished inhibition by diclofenac and piroxicam, two clinically important NSAIDs (Voltaren  TM and Feldene  TM ) , and eliminated time-dependent inhibition by nimesulide. Consistent with the recent structure of the arachidonic acid-apo COX-2 complex, diclofenac binds in the COX-2 active site in a new, inverted orientation, relative to other NSAIDs, in which its carboxylate is chelated by Ser-530 and Tyr-385 (13) . The ability of diclofenac to inhibit the R120A and Y355F mutant enzymes is consistent with this finding. Our results correspond quite closely to the 4.5-fold change in sensitivity to diclofenac inhibition exhibited by the R120E mutant of human COX-2 (26) .
Supporting evidence for the binding of diclofenac in the proximity of Ser-530 is provided by earlier studies of the S530M human COX-2 mutant, which displayed a greater than 240-fold increase in IC 50 for diclofenac over wild-type enzyme (27) . Similarly, it has been shown that diclofenac quenches the fluorescence of purified apo COX-1 but does not quench the fluorescence of the aspirin-acetylated enzyme (28) . This suggests that diclofenac does not bind in the active site of the acetylated enzyme, which would be expected if its carboxylate is chelated by Ser-530 and Tyr-385 in the unacetylated enzyme. Llorens et al. (29) recently modeled diclofenac into the active site of COX-2 and found that it could be accommodated in one of two conformations, each of which involved chelation of its carboxylate by Tyr-385 and Ser-530. The orientation that we observe in the crystal structure of diclofenac bound to COX-2 corresponds to the first conformation suggested by Llorens et al. (29) , in which the dichlorophenyl group projects down into the main channel of the active site.
Diclofenac is approximately equipotent against COX-1 and COX-2 but is more active against COX-2 than several other carboxylic acid-containing NSAIDs (30, 31) . Selinsky et al. (32) have reported the crystal structures of several competitive (ibuprofen and methylflurbiprofen) and time-dependent (flurbiprofen and alclofenac) arylcarboxylic acid inhibitors bound to COX-1. Interestingly, all of the inhibitors are bound in very similar conformations with their carboxylic acids adjacent to Arg-120. Thus, as revealed by the present mutagenesis and crystallography experiments, diclofenac exhibits a distinctive binding mode compared with several other arylacetic acid-type inhibitors when complexed to COX-2. This difference is highlighted in Fig. 6 , which compares the structure of diclofenac in the active site of COX-2 with those of indomethacin and arachidonic acid (Fig. 6, a and b, respectively) . Indomethacin binds with its carboxylate adjacent to Arg-120 and Tyr-355, consistent with the results of mutagenesis results. In contrast, diclofenac fills much of the same space occupied by arachidonic acid in the apo-COX-2 structure and is not complexed to Arg-120 and Tyr-355.
Tyr-385/Ser-530 chelation of electron-rich centers is critical for acetylation of COX-2 by aspirin and for time-dependent, non-covalent inhibition of COX-2 by diclofenac. Experiments summarized in Table II Single mutation of any of the residues abolishes inhibitory potency suggesting that concerted interaction with all three residues is essential for binding in the COX active site.
Nimesulide is an arylsulfonamide that is modestly COX-2 selective and has been assumed to partially bind in the side pocket bordered by Val-523. Guo et al. (33) reported that mutation of this residue in COX-2 to Ala, Glu, Ile, or Lys abolishes time-dependent inhibition and significantly decreases the inhibitory potency of nimesulide. Based on this observation, Fabiola et al. (34) and Garcia-Nieto et al. (35) modeled nimesulide into the active site with its sulfone group positioned in the side pocket occupied by the sulfone or sulfonamide moieties present in diarylheterocycles. The present observation that mutation of Ser-530 to Ala abolishes time-dependent inhibition but not competitive inhibition suggests nimesulide interacts with Ser-530 and possibly Tyr-385 in generating time-dependent inhibition. In contrast to diarylheterocycles such as celecoxib and rofecoxib, nimesulide contains a polar nitro group that may hydrogen-bond with Ser-530 and/or Tyr-385, in addition to a sulfone that may bind in the side pocket.
These and previous studies demonstrate that three distinct anchoring sites contribute to substrate and inhibitor binding in the COX active site. The first anchoring site lies at the junction of Arg-120 and Tyr-355 near the membrane interface. These residues drive the affinity of inhibitors such as flurbiprofen and indomethacin, as well as the productive orientation of substrate. The second major anchor point is the side pocket, defined by residues Tyr-355, Val-523, His-90, Gln-192, and Arg-513. The potency and selectivity of diarylheterocyclic inhibitors that contain phenylsulfonamides or phenylsulfones (e.g. SC-558) are in part determined by interactions in this side pocket. Finally, diclofenac and arachidonic acid in its non-productive orientation utilize interactions with Tyr-385 and Ser-530 at the top of the active site. The similarities in the binding modes of diclofenac and the non-productive orientation of arachidonic acid further supports the possibility of substrate inhibition in COX-2. It is intriguing to speculate that selectivity between COX isoforms could be incorporated into the design of inhibitors that specifically bind to each anchor point.
